Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ananth Kadambi

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
Clinical and Translational Science|April 4, 2025
Potential Meets Practicality: AI's Current Impact on the Evidence Generation and Synthesis Pipeline in Health EconomicsNichola R Naylor, Noemi Hummel, Carl de Moor, et al.
Postgraduate Medicine|August 13, 2013
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism preventionNikhil Revankar, John Patterson, Ananth Kadambi, et al.
Applied Health Economics and Health Policy|October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and futureAnanth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Clinical Pharmacology and Therapeutics|February 25, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer ReimbursementAnanth Kadambi, Nicholas C Anderson, Sandra A G Visser, et al.
Frontiers in Nephrology|May 9, 2025
Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohortGiancarlo Pesce, Mit Patel, Gaelle Gusto, et al.
Blood|May 31, 2003
A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapyBrian R Stoll, Cristiano Migliorini, Ananth Kadambi, et al.
BMC Cancer|July 1, 2021
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancerQi Zhao, Rachel Hughes, Binod Neupane, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2026
Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspectiveAndre C Kalil, Mohsen Yaghoubi, Neera Ahuja, et al.
Clinical Therapeutics|February 10, 2016
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's LymphomaNoemi Muszbek, Ananth Kadambi, Tereza Lanitis, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
Clinical and Translational Science|April 4, 2025
Potential Meets Practicality: AI's Current Impact on the Evidence Generation and Synthesis Pipeline in Health EconomicsNichola R Naylor, Noemi Hummel, Carl de Moor, et al.
Postgraduate Medicine|August 13, 2013
A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism preventionNikhil Revankar, John Patterson, Ananth Kadambi, et al.
Applied Health Economics and Health Policy|October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and futureAnanth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Clinical Pharmacology and Therapeutics|February 25, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer ReimbursementAnanth Kadambi, Nicholas C Anderson, Sandra A G Visser, et al.
Frontiers in Nephrology|May 9, 2025
Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohortGiancarlo Pesce, Mit Patel, Gaelle Gusto, et al.
Blood|May 31, 2003
A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapyBrian R Stoll, Cristiano Migliorini, Ananth Kadambi, et al.
BMC Cancer|July 1, 2021
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancerQi Zhao, Rachel Hughes, Binod Neupane, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2026
Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspectiveAndre C Kalil, Mohsen Yaghoubi, Neera Ahuja, et al.
Clinical Therapeutics|February 10, 2016
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's LymphomaNoemi Muszbek, Ananth Kadambi, Tereza Lanitis, et al.
Pageof 2